Abstract

Abstract Pathogen-specific T cells are subject to co-stimulatory and co-inhibitory signals, the balance of which promotes pathogen control while limiting immunopathology. During blood-stage Plasmodium infection, parasite-specific CD4 T cells express PD-1 and LAG-3 co-inhibitory receptors that coordinately limit CD4 T cell function. Blockade of PD-1/LAG-3 co-inhibitory signaling during chronic Plasmodium infection enhances CD4 T cell function and parasite control. In contrast to co-inhibitory receptors, the role of T cell co-stimulatory receptors during established Plasmodium infection has not been investigated. Here we show that CD4 T cells exhibit sustained expression of the co-stimulatory receptor OX40 during both human and experimental malaria. We hypothesized that co-stimulatory signaling can functionally counteract co-inhibitory circuits to maintain protective Plasmodium-specific CD4 T responses. In support of this, therapeutically activating OX40 during established experimental malaria enhances CD4 T cell activity, humoral immunity and parasite clearance. Our data also show that the effects of OX40 signaling are modified following simultaneous PD-1 blockade, which markedly impairs parasite-specific T follicular helper cell responses in an IFN-g-dependent manner. Collectively, our results identify that OX40 can be targeted to limit malaria parasite replication and reveal a previously unrecognized role of IFN-g as a negative regulator of Plasmodium-specific humoral immunity.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.